A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

Study Identifier
M02-497
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Rheumatoid Arthritis
  • Study Drug
  • adalimumab
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    This is an open-label, multi-center study in which adalimumab (D2E7) is administered

    subcutaneously 40 mg every other week in addition to current anti-rheumatic therapies.

    Patients must have active disease despite standard anti-rheumatic therapy.

    Study Locations

    No locations found.